ENCY/MYOG
RockRat,
Seems I mixed up congenital heart disease (CHD) with connective tissue disease (CTD). The ARIES trial protocol clearly lists CTD & Motte 2005 Pharm & Therapeutics in press lists 39% APAH-CTD in the ambrisentan pilot and cites Galie' 2005 JACC 46, 529. Galie' lists collagen vascular disease which I'm assuming includes connective tissue disease.
Just to fill it out, I have several sources for the ~20% CT disease in the thelin trials: Badesch Oct2005 CHEST abstract pg160S states "STRIDE-1 (n=178) and STRIDE-2 (n=246) included PAH pts with WHO class II, III, and IV: idiopathic PAH (56%) or associated with connective tissue diease (28%) or congenital heart defects (16%)." Also Galie' 2004 Cardiovascular Resrch 61, 227; and Girgis Nov2005 CHEST abstract 218S. Going from memory - of the 500+ patients in all of the STRIDE trials 110 had CT disease.
The ARIES protocol clearly excludes CHD while the STRIDE trials clearly include it. Not an auspicious first post.
Charlie
